Skip to main content

AnVil, Genomics Collaborative to Build New CV Products

NEW YORK, Nov. 5-AnVil and Genomics Collaborative will work together to develop new products and resources for the life sciences market, AnVil said today.


Using its informatics and data visualization capabilities, AnVil will analyze cardiovascular clinical data from GCI's database. The two companies will build predictive and analytic models for coronary artery disease, myocardial infarction, hyperlipidemia and hypertension.


From this collaboration, the companies hope to develop products that will be useful to pharmaceutical and biotech companies in cardiovascular drug development. They will jointly develop a marketing and business plan.


AnVil is a data management and visualization company based in Burlington, Mass.


The two companies struck a deal to develop drugs for rheumatoid arthritis in April 2002.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.